Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05815173 · ClinicalTrials.gov registry record · Phase 1
Ladarixin With Sotorasib in Advanced NSCLC
A Phase 1 study of Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 6
- Study locations
NCT05815173 is a Phase 1 study of Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 40 participants. The trial reports 6 study locations across 1 state.
The verdict
NCT05815173, a Phase 1 study of Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Sotorasib
- DRUG Ladarixin
Study Locations (6)
New York
- NYU Langone Health - Garden City
- NYU Langone Health - Mineola
- NYU Langone Health - New Hyde Park
- NYU Langone Health - New York
- NYU Langone Health - New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05815173
The ClinicalTrials.gov registry entry for NCT05815173 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation appearing as the primary indexed condition, and to 2 interventions - of which Sotorasib is the first listed.
NCT05815173 reports 6 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05815173 about?
NCT05815173 is a clinical study titled "Ladarixin With Sotorasib in Advanced NSCLC". This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in participants with advanced KRASG12C mutant non-small cell lung cancer (NSCLC).
What is the current status of trial NCT05815173?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-08-01. Estimated completion is 2027-08.
What conditions does trial NCT05815173 study?
This clinical trial studies the following conditions: Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation.
What interventions are being tested in trial NCT05815173?
The interventions under investigation include: Sotorasib (DRUG), Ladarixin (DRUG).
Who is sponsoring clinical trial NCT05815173?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05815173 being conducted?
This trial has 6 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.